Preferences help
enabled [disable] Abstract
Number of results
2012 | 7 | 2 | 154-162
Article title

Musculoskeletal manifestations of mucopolysaccharidosis type VI and effects of enzyme replacement therapy

Title variants
Languages of publication
The aim of this study was to describe the musculoskeletal manifestations of mucopolysaccharidosis VI and to assess the effectiveness of enzyme replacement therapy (ERT) with recombinant human arylsulfatase B on the bone and joint involvement in a patient with a severe phenotype of the disease. Before the initiation of ERT, the patient presented with significant range of motion (ROM) limitations at multiple joints. Flexion contractures were noticeable in all joints. After 48 weeks of ERT, improvement in active and passive shoulder flexion, as well as passive elbow and wrist flexion, was noticed. ROM improvements were reflected in patient’s enhanced self-care.
Physical description
1 - 4 - 2012
3 - 2 - 2012
  • Department of Metabolic Diseases, The Children’s Memorial Health Institute, Al. Dzieci Polskich 20, 04-730, Warsaw, Poland
  • Anthropometry Laboratory, The Children’s Memorial Health Institute, Al. Dzieci Polskich 20, 04-730, Warsaw, Poland
  • Department of Metabolic Diseases, The Children’s Memorial Health Institute, Al. Dzieci Polskich 20, 04-730, Warsaw, Poland
  • [1] Neufeld E.F., Muenzer J., The mucopolysaccharidoses, In: Scriver C.R., Beaudet A.L., Sly W.S., (Eds). The mucopolysaccharidoses, McGraw-Hill, New York, 2001, 3421–3452
  • [2] Baehner F., Schmiedeskamp C., Krummenauer F., Miebach E., Bajbouj M., Whybra C., et al., Cumulative incidence rates of the mucopolysaccharidoses in Germany. J. Inherit. Metab. Dis., 2005, 28(6), 1011–1017[Crossref]
  • [3] Malm G., Lund A.M., Mansson J.E., Heiberg A., Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr., 2008, 97(11), 1577–1581[Crossref][WoS]
  • [4] Valayannopoulos V., Nicely H., Harmatz P., Turbeville S., Mucopolysaccharidosis VI. Orphanet J Rare Dis, 2010, 5(1), 5[Crossref]
  • [5] Azevedo A., Schwartz I.V., Kalakun L., Brustolin S., Burin M.G., Beheregaray A.P.C., et al., Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin. Genet., 2004, 66(3), 208–213[Crossref]
  • [6] Hinek A., Wilson S.E., Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. The American journal of pathology, 2000, 156(3), 925–938[Crossref]
  • [7] Simonaro C.M., Ge Y., Eliyahu E., He X., Jepsen K.J., Schuchman E.H., Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc. Natl. Acad. Sci. U. S. A., 2010, 107(1), 222–227[WoS][Crossref]
  • [8] Simonaro C.M., D’Angelo M., He X., Eliyahu E., Shtraizent N., Haskins M.E., et al., Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. The American journal of pathology, 2008, 172(1), 112–122[WoS][Crossref]
  • [9] Simonaro C.M., D’Angelo M., Haskins M.E., Schuchman E.H., Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr. Res., 2005, 57(5 Pt 1), 701–707[Crossref]
  • [10] Golda A., Jurecka A., Tylki-Szymanska A., Cardiovascular manifestations of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). Int. J. Cardiol., 2011 [WoS]
  • [11] Jurecka A., Rozdzynska A., Marucha J., Czartoryska B., Wegrzyn G., Tylki-Szymanska A., Natural history of Polish patients with mucopolysaccharidosis type VI. Central European Journal of Medicine, 2011, 6(2), 163–171[Crossref]
  • [12] Giugliani R., Federhen A., Rojas M.V., Vieira T., Artigalas O., Pinto L.L., et al., Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol, 2010, 33(4), 589–604[Crossref][WoS]
  • [13] Harmatz P., Yu Z.F., Giugliani R., Schwartz I.V., Guffon N., Teles E.L., et al., Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J. Inherit. Metab. Dis., 2010, 33(1), 51–60[WoS]
  • [14] Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., et al., Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. The Journal of pediatrics, 2006, 148(4), 533–539
  • [15] Harmatz P., Ketteridge D., Giugliani R., Guffon N., Teles E.L., Miranda M.C., et al., Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics, 2005, 115(6), e681–689
  • [16] Harmatz P., Whitley C.B., Waber L., Pais R., Steiner R., Plecko B., et al., Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). The Journal of pediatrics, 2004, 144(5), 574–580[Crossref]
  • [17] McGill J.J., Inwood A.C., Coman D.J., Lipke M.L., de Lore D., Swiedler S.J., et al., Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age - a sibling control study. Clin. Genet., 2010, 77(5), 492–498[Crossref]
  • [18] Gerhardt J.J., Rondinelli R.D., Goniometric techniques for range-of-motion assessment. Phys. Med. Rehabil. Clin. N. Am., 2001, 12(3), 507–527
  • [19] Gerhardt J.J., Clinical measurements of joint motion and position in the neutral-zero method and SFTR recording: basic principles. Int. Rehabil. Med., 1983, 5(4), 161–164
  • [20] Norato D.Y.J., Giovanetti D.F., MPS I Registry health assessment questionnaire, in 9th International Symposium on Mucopolysaccharidosis and Related Diseases, 2006: Venice, p. 216
  • [21] Cieslik J., Kaczmarek M., Kaliszewska-Drozdowska M.D., [Dziecko Poznanskie’ 90. Wzrastanie, dojrzewanie, normy i metody rozwoju.]Poznan: Wydawnictwo Naukowe Bogucki. 1994
  • [22] Tylki-Szymanska A., Rozdzynska A., Jurecka A., Marucha J., Czartoryska B., Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase). Mol. Genet. Metab., 2010, 99(1), 10–17[Crossref][WoS]
  • [23] Rozdzynska A., Tylki-Szymanska A., Jurecka A., Cieslik J., Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II. Acta Paediatr., 2011, 100(3), 456–460[Crossref][WoS]
  • [24] Wraith J.E., Beck M., Lane R., van der Ploeg A., Shapiro E., Xue Y., et al., Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics, 2007, 120(1), e37–46[WoS][Crossref]
  • [25] Tylki-Szymanska A., Marucha J., Jurecka A., Syczewska M., Czartoryska B., Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J. Inherit. Metab. Dis., 2010, 33(2), 151–157[WoS][Crossref]
  • [26] Hinek A., Braun K.R., Liu K., Wang Y., Wight T.N., Retrovirally mediated overexpression of versican v3 reverses impaired elastogenesis and heightened proliferation exhibited by fibroblasts from Costello syndrome and Hurler disease patients. The American journal of pathology, 2004, 164(1), 119–131[Crossref]
  • [27] Hinek A., Mecham R.P., Keeley F., Rabinovitch M., Impaired elastin fiber assembly related to reduced 67-kD elastin-binding protein in fetal lamb ductus arteriosus and in cultured aortic smooth muscle cells treated with chondroitin sulfate. The Journal of clinical investigation, 1991, 88(6), 2083–2094[Crossref]
  • [28] Cardoso-Santos A., Azevedo A.C., Fagondes S., Burin M.G., Giugliani R., Schwartz I.V., Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): assessment of joint mobility and grip and pinch strength. J. Pediatr. (Rio. J). 2008, 84(2), 130–135[WoS][Crossref]
  • [29] Cyriax J.H., Cyriax P.J., Illustrated Manual of Orthopaedic Medicine: Butterworth-Heinemann. 1996
  • [30] Reese N.B., Bandy W.D., Joint range of motion and muscle length testing. St. Louis: Saunders/Elservier. 2010
  • [31] Muenzer J., Beck M., Eng C.M., Giugliani R., Harmatz P., Martin R., et al., Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med, 2011, 13(2), 95–101[Crossref][WoS]
  • [32] Scarpa M., Barone R., Fiumara A., Astarita L., Parenti G., Rampazzo A., et al., Mucopolysaccharidosis VI: the Italian experience. Eur. J. Pediatr., 2009, 168(10), 1203–1206[Crossref][WoS]
  • [33] Auclair D., Hein L.K., Hopwood J.J., Byers S., Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval. Pediatr. Res., 2006, 59(4 Pt 1), 538–543[Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.